Cover Story

Type 2 diabetes (T2D) is a chronic, debilitating disease with major social, fiscal, and medical costs. The prevalence of this disease is increasing markedly, and, despite the emergence of new therapies targeting insulin secretion, insulin action and/or glucose excretion, glycemic control remains generally sub-optimal, emphasizing the continued need for new therapeutic options.

The obesity medication lorcaserin, a 5-hydroxytryptamine 2C receptor (5-HT2CR) agonist, improves glycemic control in association with weight loss in obese patients with T2D. Burke and colleagues find that lorcaserin improves glycemic control in mouse models of T2D in the absence of reductions in food intake or body weight. Examining the mechanism of this effect, they reveal a necessary and sufficient neurochemical mediator of lorcaserin’s glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides. To clarify further lorcaserin’s therapeutic brain circuit, they examined the receptor target of POMC peptides. Burke et al. demonstrate that lorcaserin requires functional melanocortin 4 receptors on cholinergic preganglionic neurons to exert its effects on glucose homeostasis.

There is growing interest in brain control of peripheral glycemia and the potential for targeting the arcuate nucleus of the hypothalamus for therapy in T2D. The authors suggest that lorcaserin should be investigated in patients with T2D for blood glucose lowering therapy, in addition to its already approved licensing for body weight reduction

Full Text
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.



Ulf Smith, John Grünberg, Tobias Kroon
Sahlgrenska Academy, University of Gothenburg, Sweden
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at www.sciencedirect.com/journal/molecular-metabolism
Conferences & Events
February
23 − 27
2020
Keystone Sym­posium:
Obesity and NAFLD

Banff, Canada
February
24 − 27
2020
2nd Nuclear Receptors Conference
Nassau, Bahamas
March
1 − 5
2020
Keystone Sym­posium:
Biology of Exercise

Keystone, USA
March
10 − 11
2020
Dutch Translational Metabolism Conference
Lunteren, Netherlands
March
8 − 12
2020
Keystone Sym­posium:
Tumor Metabolism

Banff, Canada
March
22 − 26
2020
Keystone Sym­posium:
Gut-Systemic Perspective of Metabolic Disease

Santa Fe, USA
April
3 − 7
2020
Keystone Sym­posium:
Metabolism and Immunity

Keystone, USA
April
22 − 24
2020
Helmholtz:
Pseudokinases and Tribbles

Munich, Germany
Media Coverage
Supported by